Related Experiment Videos
Is platelet imipramine binding reduced in depression? A meta-analysis
1Department of Psychological Medicine, Wellington School of Medicine, New Zealand.
Biological Psychiatry
|September 1, 1994
Summary
This meta-analysis confirms that depressed individuals exhibit significantly lower platelet imipramine binding. This decrease is more pronounced in patients not taking medication, suggesting a potential biological marker for depression.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Platelet imipramine binding has been proposed as a biological marker for depressive illness.
- Previous studies, including a WHO multicenter investigation, have yielded conflicting results regarding this association.
Purpose of the Study:
- To conduct a meta-analysis of published reports to clarify the relationship between imipramine binding and depression.
- To investigate if medication status influences imipramine binding levels in depressed subjects.
Main Methods:
- Systematic review and meta-analysis of published studies comparing imipramine binding in depressed patients and healthy controls.
- Analysis focused on Bmax (maximal binding) values and included a subset of high-affinity binding studies (Kd < 1 nmol/L).
Main Results:
- A highly significant decrease in Bmax values was observed in depressed subject groups compared to controls.
- The decrease in Bmax was more pronounced in depressed individuals who had been medication-free for at least 4 weeks.
- The significant decrease in Bmax persisted even when analyzing only high-affinity binding studies.
Conclusions:
- The meta-analysis supports the hypothesis that decreased platelet imipramine binding is a valid biological marker for depression.
- The findings suggest that imipramine binding is a sensitive indicator, particularly when assessed in medication-free depressed patients.
- Further research may explore the clinical utility of imipramine binding as a biomarker in diagnosing and managing depression.